Alkermes Plc
A biopharmaceutical company that develops and sells medicines for central nervous system and addiction disorders, including Aristada for schizophrenia and Vivitrol for alcohol and opioid dependence. The name Alkermes comes from the alchemical word for a red dye made from insects, nodding to the firm's roots in drug-delivery technology. Founded in 1987 and headquartered in Dublin, it grew through the merger of two drug-delivery pioneers and now lists its shares on Wall Street.
Sold 24.15M
Granted 5.74M · Sold 4.09M
Granted 1.25M · Sold 878.1K
Granted 260.4K · Bought 20.0K · Sold 150.1K
Granted 1.13M · Sold 786.7K
Granted 367.3K · Sold 84.5K
Granted 385.2K · Sold 63.7K
Granted 464.3K · Sold 228.4K
Granted 328.5K · Sold 138.1K
Granted 814.8K · Sold 692.6K
Granted 773.8K · Sold 571.2K
Granted 249.9K · Sold 62.9K
Granted 35.3K · Bought 35.0K
Granted 939.9K · Sold 728.3K
Granted 134.3K · Bought 5.0K · Sold 51.6K
Granted 849.4K · Sold 684.5K
Granted 104.3K · Bought 1.6K · Sold 50.0K
Granted 146.8K · Bought 1.2K · Sold 76.9K
Granted 49.4K · Bought 10.0K
Granted 148.0K · Sold 148.0K
Granted 39.9K · Bought 427
Granted 45.5K
Granted 53.6K · Sold 10.8K
Granted 39.3K
Granted 60.9K · Bought 11.2K · Sold 41.3K
Granted 31.6K · Bought 1.7K
Granted 36.4K · Sold 2.0K
Granted 5.6K
Granted 24.0K
Granted 202.1K · Sold 181.0K
Granted 45.8K · Sold 32.7K
Granted 235.3K · Sold 217.1K
Granted 5.6K
Granted 298.9K · Sold 279.5K
Granted 6.3K
Granted 47.8K · Sold 44.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Elan Corp PLC +1 co-filer10% owner · 1 transaction | — | 7.75Mas of Mar 2012 | — | — | 24.15M |
| Pops Richard FDirector and CEO, Alkermes plc, Director · 282 transactions | — | 1.44M | 5.74M | — | 4.09M |
| Landine Michael JSVP, Corp Dev., Alkermes, Inc. · 255 transactions | — | 281.7Kas of Feb 2024 | 1.25M | — | 878.1K |
| Bloom Floyd EDirector · 35 transactions | — | 256.8Kas of Jul 2018 | 260.4K | 20.0K | 150.1K |
| Frates James MSVP, Alks Inc, CFO ALKS · 292 transactions | — | 247.5Kas of May 2020 | 1.13M | — | 786.7K |
| Jackson Blair CurtisEVP, Chief Operating Officer · 62 transactions | — | 241.3K | 367.3K | — | 84.5K |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. · 130 transactions | — | 229.5K | 385.2K | — | 63.7K |
| Biberstein Kathryn LEVP/CAO/CCO/CRO Alks Inc; · 130 transactions | — | 218.9Kas of Mar 2018 | 464.3K | — | 228.4K |
| Brown Iain MichaelSVP, Chief Financial Officer · 113 transactions | — | 148.2Kas of Feb 2025 | 328.5K | — | 138.1K |
| Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. · 174 transactions | — | 143.5Kas of Feb 2017 | 814.8K | — | 692.6K |
| Cooke ShaneDirector · 147 transactions | — | 135.9K | 773.8K | — | 571.2K |
| Nichols Christian ToddSVP, Chief Commercial Officer · 62 transactions | — | 109.8K | 249.9K | — | 62.9K |
| Daglio David Angelo Jr.Director · 14 transactions | — | 109.2Kas of Jul 2024 | 35.3K | 35.0K | — |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer · 119 transactions | — | 86.4K | 939.9K | — | 728.3K |
| Anstice David WDirector · 20 transactions | — | 84.9Kas of Jun 2022 | 134.3K | 5.0K | 51.6K |
| Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. · 192 transactions | — | 57.1Kas of May 2017 | 849.4K | — | 684.5K |
| Dixon Wendy LDirector · 12 transactions | — | 53.1Kas of Jun 2022 | 104.3K | 1.6K | 50.0K |
| Stejbach MarkSVP/Chief Comm Off, Alks Inc · 58 transactions | — | 51.1Kas of Mar 2018 | 146.8K | 1.2K | 76.9K |
| McKeon Brian PDirector · 18 transactions | — | 48.5K | 49.4K | 10.0K | — |
| Henwood GeraldineDirector · 18 transactions | — | 40.0Kas of Jan 2014 | 148.0K | — | 148.0K |
| snyderman nancy lynn MDDirector · 13 transactions | — | 36.2K | 39.9K | 427 | — |
| Wilson Frank AndersDirector · 14 transactions | — | 35.8K | 45.5K | — | — |
| Laurencin Cato TDirector · 24 transactions | — | 33.8K | 53.6K | — | 10.8K |
| Gaynor RichardDirector · 12 transactions | — | 33.0Kas of May 2025 | 39.3K | — | — |
| Wysenski NancyDirector · 12 transactions | — | 31.6Kas of Jul 2023 | 60.9K | 11.2K | 41.3K |
| Alva Emily PetersonDirector · 15 transactions | — | 27.3Kas of Jun 2024 | 31.6K | 1.7K | — |
| Wright Christopher IDirector · 17 transactions | — | 25.7K | 36.4K | — | 2.0K |
| Nancy J. WysenskiDirector · 2 transactions | — | 21.5Kas of Dec 2021 | 5.6K | — | — |
| Lurker NancyDirector · 10 transactions | — | 19.7K | 24.0K | — | — |
| Mitchell Paul JDirector · 135 transactions | — | 18.2Kas of May 2021 | 202.1K | — | 181.0K |
| Parisi Samuel JosephVP, Finance (Interim PAO) · 32 transactions | — | 11.1K | 45.8K | — | 32.7K |
| Breyer Robert ADirector · 95 transactions | — | 10.3Kas of May 2021 | 235.3K | — | 217.1K |
| Nancy SnydermanDirector · 2 transactions | — | 10.3Kas of Dec 2021 | 5.6K | — | — |
| Peterson RebeccaSVP, Corporate Communications · 97 transactions | — | 5.0Kas of Oct 2015 | 298.9K | — | 279.5K |
| Robinson James A. Jr.President & COO,Alkermes, Inc. · 2 transactions | — | 4.4Kas of Apr 2019 | 6.3K | — | — |
| Botkin James LSVP, Alkermes Gainesville LLC · 10 transactions | — | 2.5Kas of Dec 2013 | 47.8K | — | 44.0K |
| Skaletsky Mark BDirector · 1 transaction | — | 0as of Sep 2011 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -34.36M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.